Page 2 - Rogerj Pomerantz News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Viracta Therapeutics Announces Chief Executive Officer Leadership Succession to Drive the Next Phase of the Company s Strategic Development and Growth

/PRNewswire/ Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced the succession.

United kingdomIvor roystonMark rotheraAshleigh barretoRogerj pomerantzCambridge universityHead of investor relations corporate communicationsAegerion pharmaceuticals incPrnewswire viracta therapeutics incNatural sciencesEuropean institute for business administrationViracta therapeutics incViracta therapeutic boardChief executiveChief executive officerViracta board

ContraFect Announces Presentation of New Clinical Data From a Study Using Exebacase in the LysinDAIR Procedure on Patients With Chronic Knee Prosthetic Joint Infection

ContraFect Announces Presentation of New Clinical Data From a Study Using Exebacase in the LysinDAIR Procedure on Patients With Chronic Knee Prosthetic Joint Infection
forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.

Michael messingerRogerj pomerantzExchange commissionInfection societyContrafect corporation nasdaqContrafect corporationTristan ferryTropical diseases unitCroix rousse hospitalCivils de lyonAnnual meetingEuropean boneJoint infection societyChief executive officerBreakthrough therapyQuarterly report

Enlivex Announces Second Quarter 2022 Financial Results and Provides a Business Update

22.08.2022 - Dosed first patient in Phase I/II trial evaluating Allocetra combined with chemotherapy in patients with peritoneal metastases arising from solid cancersReceived Israeli Ministry of Health approval to initiate a Phase I/II trial evaluating Allocetra . Seite 1

Oren hershkovitzRogerj pomerantzYale cancer centerIsraeli ministry of healthKnowledge management at merck coEnlivex therapeutics ltdIsraeli ministryVice chairmanWorldwide headKnowledge managementGlobal headInfectious diseasesJohnson pharmaceuticalsVenture partnerFlagship pioneeringSeres therapeutics

ContraFect Reports Second Quarter 2022 Financial Results and Provides Corporate Update

YONKERS, N.Y., Aug. 15, 2022 ContraFect Corporation , a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents , including lysins and amurin. | August 15, 2022

Cara cassinoGarrett nicholsMichael messingerRogerj pomerantzEuropean congressContrafect corporationExchange commissionContrafect corporation nasdaqUniversity of washingtonCompany quarterly report on formDuke universityDevelopment of the companyGlobenewswire incFect corporationChief executive officerData safety monitoring board

ContraFect (CFRX) Reports Publication on Exebacase and CF-296 Demonstrating Potent In Vivo Antimicrobial Activity

ContraFect (CFRX) Reports Publication on Exebacase and CF-296 Demonstrating Potent In Vivo Antimicrobial Activity
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Rogerj pomerantzContrafect corporation nasdaqWall streetFect corporationJoint infectionCivils de lyonChief executive officer